Adverse event totals12

The totals the trial posted for each group.

1 to 12 of 12

Total	Group	Affected	At risk
Total, all-cause mortality	Phase 1B: Avelumab + Entinostat (3 mg)	5	6
Total, all-cause mortality	Phase 1B: Avelumab + Entinostat (5 mg)	4	8
Total, all-cause mortality	Phase 2: Avelumab + Placebo	26	41
Total, all-cause mortality	Phase 2: Avelumab + Entinostat	54	85
Total, other adverse events	Phase 1B: Avelumab + Entinostat (3 mg)	6	6
Total, other adverse events	Phase 1B: Avelumab + Entinostat (5 mg)	8	8
Total, other adverse events	Phase 2: Avelumab + Placebo	39	40
Total, other adverse events	Phase 2: Avelumab + Entinostat	85	85
Total, serious adverse events	Phase 1B: Avelumab + Entinostat (3 mg)	0	6
Total, serious adverse events	Phase 1B: Avelumab + Entinostat (5 mg)	4	8
Total, serious adverse events	Phase 2: Avelumab + Placebo	17	40
Total, serious adverse events	Phase 2: Avelumab + Entinostat	39	85

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02915523/event-totals